News

In addition, Apogenix and CANbridge have signed an amendment to expand the licensed territories to include Taiwan. Apogenix will continue to develop APG101 in all other territories. An

The company’s latest report states that the leading driver of this reasonably robust growth will be the anticipated launches of five biologics for the treatment of various forms

The series of three trials include a phase 1 imaging study, a phase 2 efficacy trial in adult ADHD and a phase 1 pharmacokinetics (PK) study evaluating several

The alliance seeks to discover and develop novel human therapeutic antibodies to treat a variety of cancers. Kymouse – Kymab’s human antibody discovery platform – has unparalleled diversity

CEP-9722 is a novel, orally active, small molecule selective inhibitor of PARP-1 and PARP-2 enzymes that will be developed by Checkpoint as both a monotherapy and in combination

The current dosing recommendation for patients with GT1b and compensated cirrhosis is to administer RBV with VIEKIRA PAK for 12 weeks. The FDA grants priority review designation to

The clinical trial is currently enrolling patients at multiple centers in Australia and New Zealand. MONARCH is intended to identify one or more combinations of ARC-520 and other

The research alliance is aimed at developing therapeutic small molecules that will address the unmet needs in diabetes and obesity. As per the terms of the agreement, Jubilant

The FDA has accepted the company’s investigational new drug (IND) application for the phase I/IIa study of TB-403, which is expected to start in the first quarter of